

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

| | | |
|--|--|--|
| 1. Name and Address of Reporting Person* <u>El-Hibri Fuad</u> _____ (Last) (First) (Middle) 2273 RESEARCH BOULEVARD SUITE 400 _____ (Street) ROCKVILLE MD 20850 _____ (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) CEO & Chairman |
| | 3. Date of Earliest Transaction (Month/Day/Year) 08/05/2008 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-----------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 13,800 | D | \$14 | 7,868,035 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 2,914 | D | \$14.01 | 7,865,121 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 786 | D | \$14.02 | 7,864,335 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 1,200 | D | \$14.03 | 7,863,135 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 100 | D | \$14.035 | 7,863,035 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 200 | D | \$14.0375 | 7,862,835 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 800 | D | \$14.04 | 7,862,035 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 3,006 | D | \$14.05 | 7,859,029 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 600 | D | \$14.06 | 7,858,429 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 500 | D | \$14.07 | 7,857,929 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/05/2008 | 08/08/2008 | s ⁽¹⁾ | | 494 | D | \$14.08 | 7,857,435 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | 08/06/2008 | 08/11/2008 | s ⁽¹⁾ | | 5,700 | D | \$14 | 7,851,735 ⁽¹⁾ | I | By Intervac, L.L.C. |
| Common Stock | | | | | | | | 246,992 | D | |
| Common Stock | | | | | | | | 3,665,043 ⁽²⁾ | I | By BioPharm, L.L.C. |
| Common Stock | | | | | | | | 1,599,155 ⁽³⁾ | I | By Biovac, L.L.C. |
| Common Stock | | | | | | | | 719,275 ⁽⁴⁾ | I | By Intervac Management, L.L.C. |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

